The Pharma Data

JANUARY 19, 2021

Ortho Clinical Diagnostics is a leader in in vitro diagnostics. On January 12, its VITROS SARS-CoV-2 Antigen Test for mass-scale COVID-19 testing received FDA Emergency Use Authorization. The year is starting off with a number of biopharma and life sciences initial public offerings (IPOs). TCR2 Therapeutics – The Cambridge, Mass.

In-Vitro 52

In-Vitro Production Trials Manufacturing 52

The Pharma Data

MARCH 23, 2022

Researchers at Johns Hopkins Children’s Center report evidence from lab experiments that a chemical derived from a compound found abundantly in broccoli and other cruciferous plants may offer a potentially new and potent weapon against the viruses that cause COVID-19 and the common cold. alone each year. µM) and remdesivir (for example, 0.5-3.2

Immune Response 52

Immune Response In-Vitro Research Scientist 52

The Pharma Data

JANUARY 11, 2021

Dalcetrapib is a potential anti-viral treatment that binds to the catalytic site of 3CLMpro of SARS-CoV-2 in vitro. Speaking to the Reuters Next conference, Dale Fisher, chairman of the World Health Organization’s (WHO) Outbreak Alert and Response Network, said that achievement of herd immunity in most countries is unlikely in 2021.

Vaccine 52

Vaccine Vaccination Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 17, 2020

The Elecsys Anti-SARS-CoV-2 serology test can be used to quantitatively measure antibodies in people who have been exposed to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and can play an important part in characterising a vaccine-induced immune response. The test targets antibodies against the spike protein.

Antibody 52

Antibody Vaccine Vaccination In-Vitro 52

Cloudbyz

JULY 31, 2024

In precision medicine, biomarkers are used to identify patients who will benefit from specific therapies, predict disease progression, and monitor treatment responses. Monitoring Treatment Response: Regular diagnostic testing can monitor the effectiveness of treatments by measuring changes in biomarker levels.

Gene Therapy 52

Gene Therapy Gene Medicine In-Vitro 52

pharmaphorum

NOVEMBER 2, 2021

The more targeted, bispecific functionality of bsAbs broadens the reach of antibody-mediated therapies against both solid and haematological cancers, creating novel approaches that can induce a tumour-specific immune response, target immune checkpoints, or improve payload delivery to tumour cells (Fig.

Antibody 52

Antibody Immune Response Production Engineer 52

The Pharma Data

JANUARY 11, 2021

Xiaomin Fan, Founder, President and CEO of AvantGen, “Even with the recent Emergency Use Authorization of multiple vaccines, we believe there remains an urgent need for potent antibody therapies and prophylactics for immunocompromised patients who cannot mount an adequate immune response either to the vaccine or to subsequent viral infection.

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

MARCH 16, 2021

1.351 carries another spike mutation E484K, which appears to evade the body’s immune response, possibly diminishing vaccine efficacy. The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission. 1.1.7), South Africa (B.1.351), Variants of B.1.1.7,

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccine 52

The Pharma Data

AUGUST 22, 2021

More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination. The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis.There were no cases of severe COVID-19 or COVID-19-related deaths in those treated with AZD7442.

Trials 52

Trials Antibody Vaccine Vaccination 52

XTalks

DECEMBER 12, 2024

The test builds upon the MeMed BV test, which received FDA clearance in July 2023 and a CE marking under the European In Vitro Diagnostic Devices Regulation (IVDR) in the European Union (EU). Its the first FDA-cleared host-immune response assay for accurately distinguishing between bacterial and viral infections in just 15 minutes.

In-Vitro 92

In-Vitro Immune Response Protein Sales 92

pharmaphorum

MARCH 4, 2021

There will be £22 million to fund a study to test effectiveness of combinations of different COVID-19 vaccines, as well as the world’s first study assessing effectiveness of a third vaccine dose to improve the response against current and future variants.

Vaccine 105

Vaccine Vaccination Development Life Science 105

XTalks

NOVEMBER 15, 2023

The FDA says chikungunya is an emerging global health threat as at least 5 million cases of chikungunya virus infection have been reported in the last 15 years. According to the agency, the virus is found primarily in tropical and subtropical regions of Africa, Southeast Asia and parts of the Americas where the virus-carrying mosquitos are endemic.

FDA Approval 59

FDA Approval Vaccine Vaccination In-Vitro 59

XTalks

APRIL 2, 2021

The highly awaited COVID-19 vaccine trial results address what have been three highly contested areas of concern: is the COVID-19 vaccine safe for kids, is it effective against some of the new variants of SARS-CoV-2 and how long will immunity last? How Safe and Effective is Pfizer’s COVID-19 Vaccine for Kids?

Vaccine 59

Vaccine Vaccination Trials Clinical Trials 59

The Pharma Data

MARCH 11, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the observed substantial public health impact of Israel’s nationwide immunization program.

Vaccine 52

Vaccine Vaccination Clinical Trials Clinical Trials 52

The Pharma Data

MAY 4, 2021

Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study. Tecentriq approval offers an alternative to chemotherapy for all eligible patients. We are delighted to bring Tecentriq to people in the EU with this specific type of lung cancer,” said Levi Garraway, M.D.,

Protein 52

Protein HR In-Vitro Medicine 52

XTalks

MARCH 2, 2021

As the US Food and Drug Administration (FDA) handed out an emergency use authorization (EUA) to Janssen’s COVID-19 vaccine over the weekend — making it the third authorized COVID-19 vaccine in the US — many people became laser-focused on the 66 percent average efficacy of the single-dose shot.

Vaccine 97

Vaccine Vaccination Trials Clinical Trials 97

The Pharma Data

MARCH 25, 2022

Evusheld has the potential to provide long-lasting protection to vulnerable populations such as the immunocompromised who can’t mount an adequate response to a COVID-19 vaccine, and we’ll continue to work with governments in Europe to make Evusheld available as quickly as possible.”

Antibody 52

Antibody In-Vivo Medicine Vaccine 52

The Pharma Data

MARCH 29, 2022

There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1, There is a growing body of evidence from multiple independent in vitro and in vivo (animal model) studies supporting the potential of Evusheld to protect against the BA.1,

Antibody 52

Antibody In-Vivo Vaccine Vaccination 52

XTalks

JANUARY 13, 2025

Roche has announced the FDA clearance of its VENTANA Kappa and Lambda Dual in-situ hybridisation (ISH) mRNA Probe Cocktail assay, which is designed to aid in diagnosing B-cell lymphoma, a cancer that develops in white blood cells specifically B lymphocytes or B cells of the immune system.

Immune Response 105

Immune Response In-Vivo In-Vitro Development 105

XTalks

NOVEMBER 20, 2020

The cell-based tests are designed to identify specific T cells that are activated in response to a pathogen — which in this case would be SARS-CoV-2. Traditional antibody tests for uncovering past infections involve detection of antigen-specific antibodies produced during an immune response against a pathogen.

Antibody 98

Antibody Immune Response Protein In-Vitro 98

XTalks

SEPTEMBER 14, 2020

Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. The price of that prize is incalculable.

Vaccine 92

Vaccine Vaccination Antibody Life Science 92